Edge Wealth Management’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Edge Wealth Management’s Portfolio GBT Stock Details GBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-200	Closed	-$13K	–	656
2020 Q2	$13K	Hold	200	–	–	﹤0.01%	439
2020 Q1	$10K	Hold	200	–	–	﹤0.01%	404
2019 Q4	$16K	Hold	200	–	–	﹤0.01%	365
2019 Q3	$9K	Hold	200	–	–	﹤0.01%	427
2019 Q2	$11K	Hold	200	–	–	﹤0.01%	406
2019 Q1	$11K	Hold	200	–	–	﹤0.01%	395
2018 Q4	$8K	Sell	200 -200	-50%	-$7.49K	﹤0.01%	430
2018 Q3	$15K	Sell	400 -300	-43%	-$13.3K	﹤0.01%	401
2018 Q2	$32K	Buy	700 +500	+250%	+$22.8K	0.01%	297
2018 Q1	$10K	Sell	200 -500	-71%	-$27.9K	﹤0.01%	392
2017 Q4	$28K	Sell	700 -65	-8%	-$2.43K	0.01%	281
2017 Q3	$23K	Buy	765 +435	+132%	+$12.2K	0.01%	294
2017 Q2	$9K	Hold	330	–	–	﹤0.01%	383
2017 Q1	$12K	Buy	+330	New	+$8.31K	﹤0.01%	336

Other funds holding GBT

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Edge Wealth Management's GBT Position: Q3 2020 in Review

Edge Wealth Management sold out of Global Blood Therapeutics, Inc. (GBT) in Q3 2020, closing a stake of 200 shares — an estimated $13K sold.

Edge Wealth Management first reported a position in GBT in Q1 2017 and held it in 14 quarters. The position peaked at $32K in Q2 2018. 229 funds tracked by Wall St. Rank hold GBT as of Q3 2020.

Edge Wealth Management reported no remaining Global Blood Therapeutics, Inc. position as of Q3 2020 after selling out during the quarter.
Edge Wealth Management sold 200 Global Blood Therapeutics, Inc. shares in Q3 2020, an estimated $13K.
Edge Wealth Management first reported a position in Global Blood Therapeutics, Inc. in Q1 2017 and held it in 14 quarters.
Edge Wealth Management's Global Blood Therapeutics, Inc. position peaked at $32K in Q2 2018.
229 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q3 2020.

Based on Edge Wealth Management's 13F filing for Q3 2020, filed 21 Oct 2020.